The value of Pfizer’s takeover bid may soon come to light.
The post ResApp share price frozen as $180m Pfizer takeover bid hangs in the balance appeared first on The Motley Fool Australia. –
The ResApp Health Ltd (ASX: RAP) share price has been put in the freezer as the company prepares to announce significantly consequential study results.
The healthcare technology company is currently the subject of a $180 million takeover proposed by Pfizer Inc (NYSE: PFE)âs Australian arm.
However, if its COVID-19 data confirmation studyâs results are deemed unsatisfactory, Pfizer’s bid will drop to $127 million.
Right now, ResApp shares are halted at their previous closing price of 17.5 cents each.
Letâs take a closer look at whatâs going on with ResApp on Monday.
The ResApp share price is in the freezer on Monday
The ResApp share price has been halted on Monday as the market awaits results from a clinical validation study.
The study will determine if the companyâs technology can detect COVID-19 by analysing audio of a patientâs cough as accurately as previous studies have found.
A previous pilot study found the technology â dubbed COVID Algorithm â performs with 92% sensitivity and 80% specificity.
Pfizer will offer ResApp shareholders 20.7 cents for each share they hold if the soon-to-drop results find the COVID Algorithm performs with a sensitivity of at least 86% and specificity of at least 71%.
Pfizer has also ordered the results be confirmed by an independent statistician.
If the study fails to meet the above criteria, Pfizer will offer shareholders just 14.6 cents per share.
The 20.7 cent per share bid represents a 130% premium on ResApp’s close as of 8 April. The 14.6 cent per share bid represents a premium of 62.2% on the same close.
The ResApp share price is expected to remain frozen until the results’ release or Wednesday’s open, whichever comes first.
The company noted it’s expecting to return to trade on the announcement of the results.
The ResApp share price has gained 169% over 2022 so far. Itâs also 280% higher than it was this time last year.
The post ResApp share price frozen as $180m Pfizer takeover bid hangs in the balance appeared first on The Motley Fool Australia.
Wondering where you should invest $1,000 right now?
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.* Scott just revealed what he believes could be the “five best ASX stocks” for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now
See The 5 Stocks
*Returns as of January 12th 2022
setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()
More reading
This ASX share is defying the odds to crack new 52-week highs
Why Computershare, Lithium Plus, Lynas, and ResApp shares are pushing higher
Here’s why the ResApp share price is rocketing 50% today
Why Australian Clinical Labs, Lake Resources, PolyNovo, and ResApp are rising
ResApp share price halted ahead of Pfizer takeover update
Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
